Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of KBP-042 in patients with type 2 diabetes mellitus
2017-001061-24Phase 2Completed
- Sponsor
- KeyBioscience AG
- Start
- May 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing KBP-042 with Placebo (2 arms). Primary endpoint: Change from baseline in HbA1c at 12 weeks versus placebo. Started May 2017; status: completed.
02
Drugs
KBP-042
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-001061-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001061-24.